Orlistat 96829-58-2 reducendo effusio deiectoribus adipem, unde pondus damnum
Product Detail
| Nomen | Orlistat |
| Cas numerum | 96829-58-2 |
| MOLECULA | C29h53no5 |
| Pondus | 495,73 |
| Einecs numerum | 639-755-1 |
| Point liquescens | <L ° C |
| Densitas | 0.976 ± 0.06G / CM3 (praedicta) |
| Repono condicionem | 2-8 ° C |
| Forma | Pulverem |
| Colo | Alba |
| Acetosum coefficientem | (Pka) 14.59 ± 0.23 (praedicta) |
Synonyma
(S) -2-formylamino-IV-methyl-pentanoicacid (s) -1 - [2s, oxo-II) -3 -3-hexyl, IV-oxo-II-Oxyl], (-) - tetrahydrolstattin; (- tetrahydrolstatin; (- tetrahydrolstatin; (- tetrahydrolstatin, (- tetrahydrolstatin; (- tetrahydrolstatin; (- tetrahydrolstattin; (- tetrahydrolstatin; (- tetrahydrolstatin; (- tetrahydrolstatin; (- tetrahydrolstatin; (- tetrahydrolstatin; (- tetrahydrolstr Ormyl, l-leucine (1s) -1 - [(2s, 3s) -3-Hexyl-IV-oxo-II-oxetyll] methyl], oxo-II-Oxetan (synthetase] dodecylister (synthesi), orlececylester (synthesi), orlececyestat (synthesi),);)
Pharmacological effectus
Proprietatibus
Alba crystallina pulveris, paene insolubilis in aquis, facile solutum in chloroform, maxime solutum in Methanol et Ethanol, securus Pyrolyze, liquescens punctum est XL ℃ ~ XLII ℃. Molecule est diastereomer quibus quattuor chiral centers, ad unam adsum 529nm, eius ethanol solution habet negativum optical gyrationis.
Modus actio
Orlistat est diu agens et potens specifica gastrointestinal lipase inhibitor, quod inactivates super duo enzymes per formatam a vinculo cum active Serino site de lipase in ventre et intestinum situm lipase in ventrem et parvum intestinum. Inactivated enzymes non conteram in adipem cibum in libero pingue acida et chemicalbook glycerol quod potest absorberi a corpore, ita redigo adipem attractio et reducing pondus. In addition, quidam studiis invenerunt quod Orlistat inhibits intestinorum effusio de cholesterol per inhibendo Niememann-pick C1-sicut dapibus I (Niememann, Plakc1-like1, NPC1L1).
Indicia
Hoc productum in combination cum mitis hypocaloricus victu indicavit pro diu terminus curatio obesus et overweight hominum, inter eos cum statutum periculo factores consociata cum illis cum statutum periculum factores consociata cum dolore. Hoc productum habet longum-term pondus imperium (pondus damnum, pondus sustentationem et praeventionis resiliant) efficaciam. Taking Orlistat potest reducere ADIPS-related periculo factores et incidentiae alterius ADIPS-related morbo, inter hypercholesterolemia, type II diabetes, minusires GLYCOSA tolerantia, Hyperinsulinemia, Hypertension et organum reductionem contentus.
Medicina interactiones
Potest reducere effusio Vitaminum A, D et E. potest esse cum hoc productum est simul. Si vos es taking praeparata continet vitamins A, D et E (ut quidam multivitans), vos should take this product II horas post hunc productum vel ad tempus. Populus cum type II diabete ut opus ad redigendum in dose of oris hypoglycemic agentibus (eg, sulfonylureas). Cyclosporine cooperatores administrationem potest consequuntur in decremento in plasma concentrationes de hoc. Datum usu amiodarone potest consequuntur in decrescebat absorption of posterior et reducitur efficaciam.
